Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

Switzerland, March 10, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the full ...

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt® ...

Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial ...

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial Highlights Total ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.